Browsing
     by title


0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

or enter first few letters:   
OK
Full Text
Peer Reviewed
See detailOnce-monthly oral ibandronate a new bisphosphonate dosing concept
Reginster, Jean-Yves ULg; Miller, P.; Delmas, P. et al

in Calcified Tissue International (2004), 74(S1), 85

Detailed reference viewed: 2 (2 ULg)
Full Text
Peer Reviewed
See detailOnce-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study.
Miller, Paul D; Epstein, Sol; Sedarati, Farhad et al

in Current Medical Research & Opinion (2008), 24(1), 207-13

OBJECTIVE: Oral ibandronate 150 mg is the first bisphosphonate approved for once-monthly treatment of postmenopausal osteoporosis. To investigate whether once-monthly ibandronate 150 mg increases lumbar ... [more ▼]

OBJECTIVE: Oral ibandronate 150 mg is the first bisphosphonate approved for once-monthly treatment of postmenopausal osteoporosis. To investigate whether once-monthly ibandronate 150 mg increases lumbar spine and total hip bone mineral density (BMD) to the same degree as weekly alendronate 70 mg. RESEARCH DESIGN AND METHODS: This was a 12-month, randomised, multinational, multicentre, double-blind, double-dummy, parallel-group, non-inferiority trial, conducted in 65 centres in North America, Latin America, Europe and South Africa. The study included postmenopausal women, mean lumbar spine (L2-L4) BMD T-score < -2.5 and > or = -5.0. Patients received either ibandronate 150 mg once monthly or alendronate 70 mg once weekly. MAIN OUTCOME MEASURES: Co-primary efficacy endpoints were 12-month change (%) from baseline in mean lumbar spine and total hip BMD. Changes (%) from baseline in trochanter and femoral neck BMD were also evaluated. Adverse events were monitored throughout. Once-monthly ibandronate was considered non-inferior to weekly alendronate if the lower boundary of the one-sided 97.5% confidence interval (CI) (or two-sided 95% CI) was > or = -1.41% for lumbar spine and > or = -0.87% for total hip. RESULTS: Mean relative 12-month changes were 5.1% and 5.8% (95% CI for difference, -1.13, -0.23) in lumbar spine and 2.9% and 3.0% (95% CI for difference, -0.38, 0.18) in total hip BMD with once-monthly ibandronate and weekly alendronate, respectively; meeting the non-inferiority criteria at both sites. Gains in trochanter and femoral neck BMD were similar with both treatments. Both regimens were well tolerated. TRIAL REGISTRATION: The MOTION study is registered with the International Federation of Pharmaceutical Manufacturers and Associations trial portal, under the ID number MM17385. CONCLUSIONS: Once-monthly ibandronate was shown to be clinically comparable to weekly alendronate at increasing BMD after 12 months in both the lumbar spine and total hip. [less ▲]

Detailed reference viewed: 52 (2 ULg)
Full Text
Peer Reviewed
See detailOnce-weekly alendronate produces a greater decrease in bone resorption than daily risedronate
Adami, Silvio; Felsenberg, D.; Hosking, D. et al

in Osteoporosis International (2002, November), 13(Suppl.3), 14-15

Detailed reference viewed: 11 (0 ULg)
Full Text
Peer Reviewed
See detailOnce-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production.
Cazzola, Mario; Beguin, Yves ULg; Kloczko, Janusz et al

in British Journal of Haematology (2003), 122(3), 386-93

Epoetin beta, three-times weekly (t.i.w.), is effective in reversing anaemia in lymphoproliferative disorders. The current study investigated whether an epoetin beta dose of 30,000 IU given subcutaneously ... [more ▼]

Epoetin beta, three-times weekly (t.i.w.), is effective in reversing anaemia in lymphoproliferative disorders. The current study investigated whether an epoetin beta dose of 30,000 IU given subcutaneously once weekly (q.w.) was at least as effective as 10,000 t.i.w. administration in anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin (Epo) production. Overall, 241 anaemic patients with multiple myeloma, low-grade non-Hodgkin's lymphoma or chronic lymphocytic leukaemia, all with serum Epo values </= 100 mU/ml, were randomized to receive the q.w. (n = 119) or t.i.w. (n = 122) regimen for 16 weeks. The primary efficacy criterion, i.e. the time-adjusted area under the haemoglobin-time curve from weeks 5-16, was comparable between the q.w. and t.i.w. groups [difference = - 0.20 g/dl (90% confidence interval - 0.52-0.11)]. Moreover, response rates were high and similar in both arms (72%vs 75%, q.w. and t.i.w. groups respectively). Baseline serum Epo was predictive of response: the lower serum Epo, the higher the likelihood of response (P = 0.002). Thus, epoetin beta administered q.w. is an effective and convenient treatment for anaemia in patients with lymphoproliferative disorders. Tailoring this treatment modality to subjects with defective endogenous Epo production represents a rational use of epoetin from both a medical and a community perspective. [less ▲]

Detailed reference viewed: 26 (0 ULg)
Full Text
Peer Reviewed
See detailOncogène et traitement du cancer
Burny, A.; Cleuter, Y.; Couez, D. et al

in Revue Médicale de Bruxelles (1985)

Detailed reference viewed: 4 (1 ULg)
Full Text
Peer Reviewed
See detailOncogene-induced senescence relayed by an interleukin-dependent inflammatory network.
Kuilman, Thomas; Michaloglou, Chrysiis; Vredeveld, Liesbeth C. W. et al

in Cell (2008), 133(6), 1019-1031

Oncogene-induced cellular senescence (OIS) is emerging as a potent cancer-protective response to oncogenic events, serving to eliminate early neoplastic cells from the proliferative pool. Using combined ... [more ▼]

Oncogene-induced cellular senescence (OIS) is emerging as a potent cancer-protective response to oncogenic events, serving to eliminate early neoplastic cells from the proliferative pool. Using combined genetic and bioinformatic analysis, we find that OIS is linked specifically to the activation of an inflammatory transcriptome. Induced genes included the pleiotropic cytokine interleukin-6 (IL-6), which upon secretion by senescent cells acted mitogenically in a paracrine fashion. Unexpectedly, IL-6 was also required for the execution of OIS, but in a cell-autonomous mode. Its depletion caused the inflammatory network to collapse and abolished senescence entry and maintenance. Furthermore, we demonstrate that the transcription factor C/EBPbeta cooperates with IL-6 to amplify the activation of the inflammatory network, including IL-8. In human colon adenomas, IL-8 specifically colocalized with arrested, p16(INK4A)-positive epithelium. We propose a model in which the context-dependent cytostatic and promitogenic functions of specific interleukins contribute to connect senescence with an inflammatory phenotype and cancer. [less ▲]

Detailed reference viewed: 9 (1 ULg)
Peer Reviewed
See detailLes oncogènes dans les cancers du sein.
Gol-Winkler, Rose; Pasleau, Françoise ULg; Dijkmans, Huguette

Conference (1990)

Detailed reference viewed: 50 (2 ULg)
See detailOncogenic human papillomavirus could directly interact with Natural Killer cells
Renoux, Virginie; Bastin, Renaud ULg; Boniver, Jacques ULg et al

Poster (2012, May 04)

Detailed reference viewed: 8 (4 ULg)
See detailOncogenic human papillomavirus could directly interact with Natural Killer cells
Renoux, Virginie; Bastin, Renaud ULg; Boniver, Jacques ULg et al

Poster (2012, June 22)

Detailed reference viewed: 5 (2 ULg)
See detailOncogenic human papillomavirus could directly interact with Natural Killer cells
Renoux, Virginie; Bastin, Renaud ULg; Boniver, Jacques ULg et al

Poster (2012, December 10)

Detailed reference viewed: 18 (13 ULg)
Full Text
See detailOncogenic human papillomavirus could directly interact with natural killer cells
Renoux, V; Bastin, R; Langers, I et al

Poster (2012)

Detailed reference viewed: 13 (0 ULg)
Peer Reviewed
See detailOncogenic potential of Tax requires phosphorylation on serines 106 et 293.
Willems, Luc ULg; Grimonpont, Catherine; Kerkhofs, Pierre et al

in Virus Research (1997), 47(2 -Special Issue), 121-122

Detailed reference viewed: 3 (0 ULg)
See detailOncogenome sequencing: is it sustainable?
Massart, Sébastien ULg; Alexandre, L.

Conference (2012, June)

Detailed reference viewed: 7 (1 ULg)
Full Text
Peer Reviewed
See detailOncological Applications of Positron Emission Tomography with Fluorine-18 Fluorodeoxyglucose
Rigo, Pierre ULg; Paulus, Patrick; Kaschten, Bruno et al

in European Journal of Nuclear Medicine (1996), 23(12), 1641-74

Positron emission tomography (PET) is now primarily used in oncological indication owing to the successful application of fluorine-18 fluorodeoxyglucose (FDG) in an increasing number of clinical ... [more ▼]

Positron emission tomography (PET) is now primarily used in oncological indication owing to the successful application of fluorine-18 fluorodeoxyglucose (FDG) in an increasing number of clinical indications at different stages of diagnosis, and for staging and follow-up. This review first considers the biological characteristics of FDG and then discusses methodological considerations regarding its use. Clinical indications are considered, and the results achieved in respect of various organs and tumour types are reviewed in depth. The review concludes with a brief consideration of the ways in which clinical PET might be improved. [less ▲]

Detailed reference viewed: 39 (1 ULg)
Full Text
Peer Reviewed
See detailOncologie gastro-intestinale
Coucke, Philippe ULg; FREI; FELLEY et al

in Médecine et Hygiène (1999), 57(2240), 213-217

Même si aucune acquisition nouvelle n'est venue embaumer l'atmosphère encore trop souvent grisâtre de l'oncologie gastro-intestinale en 1998, la nécessité d'un consilium préthérapeutique associant ... [more ▼]

Même si aucune acquisition nouvelle n'est venue embaumer l'atmosphère encore trop souvent grisâtre de l'oncologie gastro-intestinale en 1998, la nécessité d'un consilium préthérapeutique associant chirurgiens, endoscopeurs, oncologues et radio-oncologues s'impose avec encore plus de fermeté, pour tous les cancers digestifs. Les patients devraient autant que possible être inclus dans des protocoles d'études bien conduits et bénéficier d'une chirurgie oncologique optimale. [less ▲]

Detailed reference viewed: 36 (2 ULg)
Full Text
Peer Reviewed
See detailoncologie gastro-intestinale
Frei, A.; Coucke, Philippe ULg; Felley, C. et al

in Revue Médicale Suisse (1999), 760

Detailed reference viewed: 24 (0 ULg)
Peer Reviewed
See detailThe oncoprotein Bcl-3 can facilitate NF-kappa B-mediated transactivation by removing inhibiting p50 homodimers from select kappa B sites.
Franzoso, G.; Bours, Vincent ULg; Azarenko, V. et al

in EMBO Journal (1993), 12(10), 3893-901

Previously we have proposed a role for Bcl-3 in facilitating transactivation through kappa B sites by counteracting the inhibitory effects of bound, non-transactivating homodimers of the p50 subunit of NF ... [more ▼]

Previously we have proposed a role for Bcl-3 in facilitating transactivation through kappa B sites by counteracting the inhibitory effects of bound, non-transactivating homodimers of the p50 subunit of NF-kappa B. Such homodimers are abundant for example in nuclei of unstimulated primary T cells. Here we extend the model and provide new evidence which fulfills a number of predictions. (i) Bcl-3 preferentially targets p50 homodimers over NF-kappa B heterodimers since the homodimers are completely dissociated from kappa B sites at concentrations of Bcl-3 which do not affect NF-kappa B. (ii) Select kappa B sites associate very strongly and stably with p50 homodimers, completely preventing binding by NF-kappa B. Such kappa B sites are likely candidates for regulation by p50 homodimers and Bcl-3. (iii) Bcl-3 and p50 can be co-localized in the nucleus, a requirement for active removal of homodimers from their binding sites in vivo. (iv) The ankyrin repeat domain of Bcl-3 is sufficient for the reversal of p50 homodimer-mediated inhibition, correlating with the ability of this domain alone to inhibit p50 binding to kappa B sites in vitro. Our data support the model that induction of nuclear Bcl-3 may be required during cellular stimulation to actively remove stably bound p50 homodimers from certain kappa B sites in order to allow transactivating NF-kappa B complexes to engage. This exact mechanism is demonstrated with in vitro experiments. [less ▲]

Detailed reference viewed: 5 (0 ULg)
Peer Reviewed
See detailThe oncoprotein Bcl-3 directly transactivates through kappa B motifs via association with DNA-binding p50B homodimers.
Bours, Vincent ULg; Franzoso, G.; Azarenko, V. et al

in Cell (1993), 72(5), 729-39

Bcl-3 is an I kappa B-related protein with ankyrin repeat motifs. Its gene is located at a site of recurrent translocations in a subset of B cell chronic lymphocytic leukemias. Bcl-3 associates tightly ... [more ▼]

Bcl-3 is an I kappa B-related protein with ankyrin repeat motifs. Its gene is located at a site of recurrent translocations in a subset of B cell chronic lymphocytic leukemias. Bcl-3 associates tightly with p50B (NFKB2, p52) homodimers in cells, and together these proteins form a ternary complex with DNA at kappa B sites. Such an association functionally leads to a novel and potent form of transactivation through the kappa B motif: the tethering of Bcl-3 to DNA via the p50B homodimers allows Bcl-3 to transactivate directly, while p50B homodimers alone cannot. Transactivation mediated by Bcl-3 requires two cooperating domains located amino- and carboxy-terminal to the ankyrin domain. Bcl-3 is localized to the nucleus, and a Bcl-3-p50B complex is detected in certain lymphoid cells. Our data reveal a novel role for Bcl-3, distinct from that of the inhibitor I kappa B. The results have implications for tumorigenesis. [less ▲]

Detailed reference viewed: 7 (5 ULg)
Full Text
Peer Reviewed
See detailOncoviral bovine leukemia virus G4 and human T-cell leukemia virus type 1 p13(II) accessory proteins interact with farnesyl pyrophosphate synthetase
Lefebvre, Laurent; Vanderplasschen, Alain ULg; Ciminale, Vincenzo et al

in Journal of Virology (2002), 76(3), 1400-1414

G4 and p13(II) are accessory proteins encoded by the X region of bovine leukemia virus and human T-cell leukemia virus type 1 (HTLV-1), respectively. Disruption of the G4 and p13(II) open reading frames ... [more ▼]

G4 and p13(II) are accessory proteins encoded by the X region of bovine leukemia virus and human T-cell leukemia virus type 1 (HTLV-1), respectively. Disruption of the G4 and p13(II) open reading frames interferes with viral spread in animal model systems, indicating that the corresponding proteins play a key role in viral replication. In addition, G4 is oncogenic in primary cell cultures and is absolutely required for efficient onset of leukemogenesis in sheep. To gain insight into the function of these proteins, we utilized the yeast two-hybrid system to identify protein partners of G4. Results revealed that G4 interacts with farnesyl pyrophosphate synthetase (FPPS), a protein involved in the mevalonate/squalene pathway and in synthesis of FPP, a substrate required for prenylation of Ras. The specificity of the interaction was verified by glutathione S-transferase (GST) pull-down assays and by coimmunoprecipitation experiments. Furthermore, confocal microscopy showed that the subcellular localization of G4 was profoundly affected by FPPS. The G4 protein itself was not prenylated, at least in rabbit reticulocyte lysate-based assays. The domain of G4 required for binding to FPPS was restricted to an amphipathic alpha-helix rich in arginine residues. Subtle mutation of this alpha-helix abrogated G4 oncogenic potential in vitro, providing a biological relevance for FPPS-G4 complex formation in cells. Finally, HTLV-1 p13(II) was also found to specifically interact with FPPS (in yeast as well as in GST pull-down assays) and to colocalize with G4 in mitochondria, suggesting a functional analogy between these oncoviral accessory proteins. Identification of FPPS as a molecular partner for p13(II) and G4 accessory proteins opens retrovirus-induced leukemia. [less ▲]

Detailed reference viewed: 14 (2 ULg)